Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25712268 | 0.90 | ALDH1A1 (0.31) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL22525090 | 0.83 | — | — | |
| SCHEMBL17732553 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL24858818 | 0.78 | POLA1 (0.40) | — | |
| SCHEMBL24512490 | 0.75 | TK1 (0.34) | LMNACYP1A2 | |
| SCHEMBL29323074 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL16000610 | 0.74 | — | — | |
| SCHEMBL29323172 | 0.70 | ALDH1A1 (0.37) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL25458669 | 0.70 | PYGM (0.44) | ALDH1A1LMNA | |
| SCHEMBL18503408 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-9334300-B2 | Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates | MBC PHARMA, INC. (US) | 2016-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | ALDH1A1 1929/4885LMNA 424/4885ALB 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.